LOS ANGELES, April 9, 2018 —CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens.
Recognizing escalating healthcare costs, CURE and United Smart Cities will seek to promote education and innovation in delivering cost-effective and sustainable treatments to the world’s population.
“CURE was founded on the principles of affordability and global accessibility of medications,” said Rob Davidson, CEO of Cure Pharmaceutical. “We are driven to finding healthcare solutions for people of all ages and demographics and we are honored to be in service to this cause with United Smart Cities. Our mutual goal is to invigorate health and elevate living standards through education and sustainable new technologies.”
“We are happy to add CURE Pharmaceutical into United Smart Cities’ private sector partnership pool,” said Kari Eik, United Smart Cities Co-Director, and Secretary General of OiER. “Health infrastructure is a key focus area for the United Smart Cities program, and we look forward to engaging with health solution providers from diverse sectors to jointly contribute to the development of robust, sustainable health infrastructure for smart sustainable cities worldwide.”
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com